GLP-1 microdosing is an emerging practice where individuals take sub-therapeutic doses of GLP-1 medications typically 0.05 to 0.25mg of semaglutide weekly versus the standard 0.25 to 2.4mg to minimize side effects while achieving gradual weight loss and metabolic benefits
North America led the market by securing a market share of 49.7% in 2024
Someone aiming to lose 20 pounds may achieve that in 8 to 12 months, while a person targeting a 50+ pound reduction typically needs 18 to 30 months for safe, sustainable results
With a potential new side effect now brought to consumers attention, its likely even more will be deterred
I know families who have written all sorts of rules about this: no screens at the table, no screens upstairs, phones plugged in at the house entryway and not touched etc
A Phase III clinical trial of exenatide (again, the Bydureon formulation) is now underway at 6 sites in the UK ( Click here to read more about this)